RESULTS

Fourth Quarter of 2021

1

DISCLAIMER

This presentation does not contain any confidential material and may include publicly available market information that has not been independently verified by Reig Jofre.

This information is provided in summary form and does not purport to be complete. The information contained in this presentation should not be construed as advice or a recommendation to investors or potential investors to hold, purchase or sell Reig Jofre shares and does not take into consideration your specific investment objectives, financial situation or needs.

This presentation may contain forward-looking statements including statements about Reig Jofre's intent, beliefs and expectations with respect to business and operations, market conditions, operating income and financial conditions, capital adequacy, specific provisions and risk management practices. Readers should not rely unduly on these forward-looking statements.

Reig Jofre is under no obligation to publicly disclose the results of revising these forward-looking statements to reflect the occurrence of unanticipated events. Although the information forecast has been prepared with due care and attention, the actual results may vary materially either positively or negatively. Forecasts and hypothetical examples are subject to uncertainty and contingenciesbeyondReig Jofre's control.

Past performance is no guarantee of future results.

P A G E

TABLE OF CONTENTS

0 1 2 0 2 1 R E S U L T S

0 2 I N C O M E S T A T E M E N T A N D B A L A N C E S H E E T

03 O U T L O O K F O R 2 0 2 2

04 R J F S H A R E P E R F O R M A N C E

R J F S H A R E P E R F O R M A N C E

P A G E

Q4 2021

RESULTS

2 0 2 1

01

P A G E

2021 RESULTS

REIG JOFRE's revenues and EBITDA grew by 3% in 2021

SALES+3%

€236.2 million

EBITDA+3%

€27.3 million

CONSOLIDATED -10%

REVENUE

€5.1 million

  • The cumulative sales figure in 2021 reached €236 million, exceeding the 2020 year-end by 3%. Recovery from the sale of prescription medical products from the Speciality Pharmacare division, and the good performance of Forté Pharma's range of food supplements, offset the lower consumption of essential medicines and the antibiotics market's fall.
  • European markets grew by 4%, highlighting the progression in France, Benelux, UK and Poland. Revenues in the rest of the world increased by 3%, while the domestic market is 1% higher than the previous year.
  • The Speciality Pharmacare division shows the highest growth, 14%, thanks to an 18% increase in dermatology products and good performance in the osteoarticular product range, especially in international markets.
  • The Consumer Healthcare division also achieved a significant annual growth of 8%, driven by strong demand in the second half in our main markets: France and Benelux.
  • In 2021, the Group's EBITDA reached €27.3 million, with a 3% increase over the previous year.
  • Expenditure associated with the start-up of the new plant in Barcelona and higher amortisations had an impact on the year's consolidated revenue, which stands at €5.1 million, which represents a 10% drop compared to 2020.
  • Industrial investment reached €13.1 million. The greatest impacts are associated with completing the new injectables plant in Barcelona and full renovation of facilities undertaken in the Toledo plant.
  • The Debt/EBITDA ratio stands at 2.5 compared to 2.1 at the end of the previous year.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Laboratorio Reig Jofre SA published this content on 28 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 February 2022 10:51:00 UTC.